GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease?

[reedboat2]

urldefense.proofpoint.com/v...

[park_bear]

This review says that the results for the phase 3 Exenatide-PD3 trial (NCT04232969) are not completed. Apparently it was written prior to news of the results. Unfortunately it was a fail on both primary and secondary endpoints. This was the only phase 3 trial among the trials listed. The various Phase 2 trials listed are also shown as no result available. Whatever the phase 2 results for Exenatide turn out to be will be outweighed by the phase 3 result. There are Phase 2 trials for some other drugs running, so the story is not yet complete.

clinicaltrialsarena.com/new...

[reedboat2 in reply to park_bear]

Thanks for the clarification, PB. A friend of mine has been taking GLP-1 Receptor Agonists for years for Type2 Diabetes. It’s something to keep an eye on - JG

[garygjs in reply to reedboat2]

If PD begins in the gut - as has has been posited by some ( a dodgy gut giving rise to misfolded proteins which make their way to the noggin via the vagus nerve) - then GLP-1 Agonists (which are effectively inducing gastroparesis) are likely an absolutely dreadful idea.

This, incidentally, wouldn't show in any data we have on GLP-1s... it would happen across decades.

If you have PD - and are already disposed towards slow motility - then adding these into the mix looks to me like adding fuel to a fire.

If PD is the result of some broad inflammatory cascade then the fat loss + attendant diminution in inflammation that is likely to follow from GLP-1 use could be pretty handy.